show stori continu mix
mix earn disappoint clearli expect
low tough us see much downsid point stock trade
price-to-earnings focu remain cynosur rev
manag offici lower expect took write-down
busi million write-down billion ev deal isnt entir
surpris segment perform poor plagu sale forc turnov
follow acquisit manag lower expect
believ posit busi around revenu y/i
comp hope clear deck cynosur
reset expect point compani start drive upsid
busi messag compani stress earn call manag
note feel much better posit busi today
quarter ago sale forc hire essenti complet notabl win
tout check suggest market healthi product
stack compar peer ultim come execut
continu believ fixabl pleas see report detail tool
 dx aesthet survey say healthi demand need execut
continu lot convict thing like holog
thesi includ new product intern growth signific free cash flow
gener busi revenu beat forecast split equal
organ growth fx ep came line forecast despit lower
cynosur forecast maintain ep guidanc
repres growth y/i gener meaning free cash flow
manag activ deploy toward buy-back million pay
convert debt offici retir last week continu see valu
thesi given durabl double-digit ep growth reiter
overweight rate lower price
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
mix earn disappoint clearli expect low
tough us see much downsid point stock trade
price-to-earnings focu remain cynosur rev manag
offici lower expect took write-down busi
million write-down billion ev deal
perform poor plagu sale forc turnov follow acquisit
manag lower expect believ posit busi
around revenu y/i comp hope
clear deck cynosur reset expect point
compani start drive upsid busi messag compani
stress earn call manag note feel much better
posit busi today quarter ago sale forc hire
essenti complet notabl win tout check suggest market
healthi product stack compar peer ultim
come execut continu believ fixabl pleas see
report detail tool dx aesthet survey say healthi demand
need execut
continu lot convict thing like holog
thesi includ new product intern growth signific free cash flow
gener busi revenu beat forecast split equal
organ growth fx ep came line forecast despit lower
cynosur forecast maintain ep guidanc
repres growth y/i gener meaning free cash flow
manag activ deploy toward buy-back million pay
convert debt offici retir last week continu see valu
thesi given durabl double-digit ep growth reiter overweight
lower price driven lower outlook cynosur
price repres ebitda forecast billion
prior price target repres prior ebitda forecast billion
due modest outlook cynosur busi reduc
revenu guidanc howev due solid expens control compani maintain
ep forecast revenu anticip rang billion
million midpoint previou guidanc repres report growth
constant currenc growth low-singl digit organ
growth estim midpoint addit estim three fewer sell
day headwind top line manag remain
confid long-term outlook cynosur busi follow major sale
forc disrupt post acquisit improv busi take longer
expect result wrote goodwil associ asset
million quarter compani expect cynosur revenu
materi million pro-forma revenu addit
busi expect declin y/i return growth
reduct guidanc write-down asset disappoint
doesnt chang view attract medic aesthet market
holog abil acceler cynosur busi double-digit growth longer-
ep guidanc anticip rang line previou guidanc
impli growth despit reduct revenu guidanc
remain confid abil drive oper effici hit
ep target compani expect non-gaap tax rate year
midpoint previou guidanc well dilut share count
million previou forecast million guidanc assum capit
alloc asid call convert note guidanc impli
revenu growth lead revenu rang million
estim organ growth guidanc compani expect adjust ep
rang describ previous cynosur expect y/i
revenu increas y/i million exclud result blood
screen busi success divest cynosur organ
revenu grew y/i quarter blood screen contribut million
cynosur ad million sequenti quarter growth follow chang
manag late compani post anoth strong quarter intern
growth ex-portfolio chang
revenu organ growth
compani saw healthi growth breast health diagnost cynosur
gyn surgic weaker expect
diagnost revenu segment revenu grew y/i ex-fx molecular
diagnost increas y/i ex-fx driven increas market share util
panther system notabl intern diagnost grew y/i organ
driven women health offer compani full menu sexual
health viral load respiratori assay market global total estim
panther place diagnost custom includ
unit state remind compani complet sale blood screen
busi januari cytolog perinat revenu decreas ex-fx
million
breast revenu revenu grew y/i ex-fx despit increas
market penetr geniu mammographi placement remain strong
quarter call mcmillan note strong placement eas concern
potenti mammographi cliff addit strong servic revenu
million quarter driven larger instal base compani start
see contribut affirm biopsi system softer breast health revenu
y/i partial off-set anoth strong quarter intern revenu
y/i ex-fx estim compani us placement
quarter estim bring cumul placement
cynosur rev holog close acquisit cynosur march
busi contribut million revenu quarter sale
improv y/i easi comp though q/q typic
softer call manag reset expect busi cite
sale forc disrupt main reason would meet full year expect
said compani believ cynosur eventu growth engin
model cynosur revenu million sequenti
gyn surgic revenu declin y/i ex-fx million
manag continu see strong perform myosur post
ex-fx growth said novasur weaken growth ex-fx remind
benefit competit product recal novasur annual
compani assum modest growth
revenu segment
skelet health revenu increas y/i ex-fx million
segment specif saw growth dxa product servic manag note
quarterli sale expect improv cours year driven
better portfolio sell increas interest horizon bone densitometri system
bodi composit test new mini c-arm product
breast health deliv organ growth driven combin resili us
placement servic growth new product intern share gain
improv convict segment grow low-singl digit
compani approach penetr instal base compani
conserv tone around placement opportun compani exhaust
multi-ord placement opportun larger hospit leav smaller commun
hospit custom gener price sensit order size smaller
make placement opportun harder come manag roll
addit tier product help penetr smaller site unlik cycl
believ help extend tail placement eas concern
specif breast imag compani report million revenu
y/i ex-fx driven primarili strength intern us breast health busi
improv y/i howev intern busi grew y/i ex-fx along
stronger sale system growth driven servic new product
revenu remind recent launch brevera expect system
contribut grow quarter addit compani note amid
competit environ gain market share put growth
perspect chart note estim placement end
total estim penetr amongst exist
custom base stabl sequenti trend placement consist fda mqsa
data publish describ placement rate larg steadi
mammographi upgrad cycl drive growth servic revenu due higher price
remind saw acceler ffdm placement rate earli
acceler driven factor
includ reimburs
mammographi addit renew invest sale market ge
siemen back launch new unit keep mind calendar fourth
quarter year typic season weak given time rsna
confer loss sell week
quarterli placement ffdm unit
unit placement unit placementstot unitsdigit unitsquarterli unit place barclay holog inc
monthli placement ffdm unit
made signific progress de-lever follow cynosur
acquisit reach point capit deploy repres real
opportun compani exit quarter net debt/ebitda ratio
expect declin end follow portfolio chang
compani leverag remain point pursu addit capit
deploy believ compani priorit tuck-in acquisit absent
would expect compani pay debt repurchas share believ gyn
surgic diagnost like area could augment
diagnost point care poc notabl gap compani portfolio
critiqu poc market mani compani
success gener profit said point care one
fastest grow area coverag sustain secular tailwind relat
consumer healthcar would natur cross-sel opportun
hospit touch point panther mdx system
gyn surgic could also attract area tuck-in addit product
 ad product gyn surgic portfolio would better leverag gyn
sale forc third product market ob/gyn
barclay holog inc
net debt ttm ebitda
compani post strong intern growth fourth consecut quarter
prove commerci effort abroad bear fruit constant currenc
basi exclud blood screen cynosur total intern revenu increas
y/ strength led breast health constant currenc
diagnost constant currenc ex-blood screen encourag
strength compani molecular diagnost busi driven strength
panther placement compani women health aptima assay manag
previous note viral load revenu remain small compani encourag
growth seen intern
non-gaap ep increas y/i in-lin forecast quarter
non-gaap ep growth
gross margin declin y/i driven primarili product
mix due blood screen divestitur divest blood screen busi carri
gross margin accret compani averag addit gross margin
impact geograph mix complet quarter lower-margin cynosur
debt non-gaap epsy/i growth barclay holog inc
product sale gross margin expect flat slightli improv rest
year cynosur consum mix increas percentag revenu
help margin time
gross margin annual improv
oper margin declin y/i due divestitur blood screen
busi acquisit cynosur quarter oper margin
quarter declin y/i rel compani averag divest blood
screen busi higher margin cynosur margin dilut given
acquir asset commerci infrastructur oper expens pressur holog
oper margin go forward geograph mix also repres headwind
margin quarter sale market ex-comp came revenu
q/q expens revenu ex-comp flat q/q ex-
comp revenu declin y/i
adjust ex-comp sg trend
marginimprov product revssg rev barclay holog inc
 mm except ep reportedincom profit ebitda ebit pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
